Delivery Order SPE2DB20D2014-SPE2DB25FC53C
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $4,964.46 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on July 22, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 receptor agonist used for weight management and diabetes treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $32,583.67 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $38,515.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injections on July 18, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The delivery is scheduled for completion by July 21, 2025, with performance at the...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $67,987.81 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.56 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,311.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order with an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency has awarded a $13,342.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units). The contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a small-value transaction executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance location is AmerisourceBergen's corporate office in...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC53CDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,396.80 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.9 million through December 2026. The place of performance is located in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters and a major pharmaceutical distribution hub supporting federal medical procurement. Zepbound is a GLP-1 receptor agonist indicated for weight management, reflecting the DLA's procurement of specialized pharmaceutical products to support military healthcare systems. AmerisourceBergen serves as a critical pharmaceutical distributor for the Department of Defense medical supply chain, leveraging its comprehensive global pharmaceutical support vehicle to deliver brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to the Defense Health Agency and other federal healthcare systems. The DLA's Pharmaceutical Prime Vendor Global Program is structured to accommodate multiple regional contractors, positioning AmerisourceBergen as one of several key vendors in this strategic approach to military medical logistics.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.4k | 7/22/25 |